These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 29992354)

  • 1. An early clinical trial of Salirasib, an oral RAS inhibitor, in Japanese patients with relapsed/refractory solid tumors.
    Furuse J; Kurata T; Okano N; Fujisaka Y; Naruge D; Shimizu T; Kitamura H; Iwasa T; Nagashima F; Nakagawa K
    Cancer Chemother Pharmacol; 2018 Sep; 82(3):511-519. PubMed ID: 29992354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies.
    Badar T; Cortes JE; Ravandi F; O'Brien S; Verstovsek S; Garcia-Manero G; Kantarjian H; Borthakur G
    Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):433-438.e2. PubMed ID: 25795639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice.
    Haklai R; Elad-Sfadia G; Egozi Y; Kloog Y
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):89-96. PubMed ID: 17909812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer.
    Laheru D; Shah P; Rajeshkumar NV; McAllister F; Taylor G; Goldsweig H; Le DT; Donehower R; Jimeno A; Linden S; Zhao M; Song D; Rudek MA; Hidalgo M
    Invest New Drugs; 2012 Dec; 30(6):2391-9. PubMed ID: 22547163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salirasib in the treatment of pancreatic cancer.
    Bustinza-Linares E; Kurzrock R; Tsimberidou AM
    Future Oncol; 2010 Jun; 6(6):885-91. PubMed ID: 20528225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations.
    Riely GJ; Johnson ML; Medina C; Rizvi NA; Miller VA; Kris MG; Pietanza MC; Azzoli CG; Krug LM; Pao W; Ginsberg MS
    J Thorac Oncol; 2011 Aug; 6(8):1435-7. PubMed ID: 21847063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors.
    Tsimberidou AM; Rudek MA; Hong D; Ng CS; Blair J; Goldsweig H; Kurzrock R
    Cancer Chemother Pharmacol; 2010 Jan; 65(2):235-41. PubMed ID: 19484470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A first-in-human phase I trial of daily oral zelenirstat, a N-myristoyltransferase inhibitor, in patients with advanced solid tumors and relapsed/refractory B-cell lymphomas.
    Sangha R; Jamal R; Spratlin J; Kuruvilla J; Sehn LH; Beauchamp E; Weickert M; Berthiaume LG; Mackey JR
    Invest New Drugs; 2024 Aug; 42(4):386-393. PubMed ID: 38837078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HRAS as a potential therapeutic target of salirasib RAS inhibitor in bladder cancer.
    Sugita S; Enokida H; Yoshino H; Miyamoto K; Yonemori M; Sakaguchi T; Osako Y; Nakagawa M
    Int J Oncol; 2018 Aug; 53(2):725-736. PubMed ID: 29901113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid).
    Zundelevich A; Elad-Sfadia G; Haklai R; Kloog Y
    Mol Cancer Ther; 2007 Jun; 6(6):1765-73. PubMed ID: 17541036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer.
    Rotblat B; Ehrlich M; Haklai R; Kloog Y
    Methods Enzymol; 2008; 439():467-89. PubMed ID: 18374183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salirasib (farnesyl thiosalicylic acid) for brain tumor treatment: a convection-enhanced drug delivery study in rats.
    Goldberg L; Ocherashvilli A; Daniels D; Last D; Cohen ZR; Tamar G; Kloog Y; Mardor Y
    Mol Cancer Ther; 2008 Nov; 7(11):3609-16. PubMed ID: 19001442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.
    Herbst RS; Maddox AM; Rothenberg ML; Small EJ; Rubin EH; Baselga J; Rojo F; Hong WK; Swaisland H; Averbuch SD; Ochs J; LoRusso PM
    J Clin Oncol; 2002 Sep; 20(18):3815-25. PubMed ID: 12228201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.
    Creemers GJ; Gerrits CJ; Eckardt JR; Schellens JH; Burris HA; Planting AS; Rodriguez GI; Loos WJ; Hudson I; Broom C; Verweij J; Von Hoff DD
    J Clin Oncol; 1997 Mar; 15(3):1087-93. PubMed ID: 9060549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
    Guo F; Letrent SP; Munster PN; Britten CD; Gelmon K; Tolcher AW; Sharma A
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):97-109. PubMed ID: 17805538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New derivatives of farnesylthiosalicylic acid (salirasib) for cancer treatment: farnesylthiosalicylamide inhibits tumor growth in nude mice models.
    Goldberg L; Haklai R; Bauer V; Heiss A; Kloog Y
    J Med Chem; 2009 Jan; 52(1):197-205. PubMed ID: 19072665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of salirasib (S-trans,trans-farnesylthiosalicylic acid) in human plasma using liquid chromatography-tandem mass spectrometry.
    Zhao M; He P; Xu L; Hidalgo M; Laheru D; Rudek MA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Jun; 869(1-2):142-5. PubMed ID: 18534927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ras chaperones: new targets for cancer and immunotherapy.
    Kloog Y; Elad-Sfadia G; Haklai R; Mor A
    Enzymes; 2013; 33 Pt A():267-89. PubMed ID: 25033809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
    Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
    Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid).
    Blum R; Elkon R; Yaari S; Zundelevich A; Jacob-Hirsch J; Rechavi G; Shamir R; Kloog Y
    Cancer Res; 2007 Apr; 67(7):3320-8. PubMed ID: 17409441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.